AB Science announces recruitment of first patient in phase 2B/3 study of … – MarketWatch (press release)

August 4, 2011 by  
Filed under Osteo-Arthritis News

AB Science announces recruitment of first patient in phase 2B/3 study of
MarketWatch (press release)
Its objective is to compare the efficacy and safety of masitinib at 3 and 6 mg/kg/day to methotrexate in the treatment of patients with active rheumatoid arthritis with inadequate response to: i) methotrexate; ii) any Disease-modifying anti-rheumatic

and more »

More Info: Click here

“Finally, you can have the same Revolutionary Yoga Program top athletes use for TOTAL mind-body fitness ... in just 30 minutes a day!”

Speak Your Mind

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!

This blog is kept spam free by WP-SpamFree.

Access denied for user ''@'localhost' (using password: NO)